Asarina Pharma to release historic Phase IIb PMDD data on schedule
Asarina Pharma expects to release top-line results of its Phase IIb PMDD study on schedule at the end of April. Asarina Pharma’s other studies on menstrual migraine and Tourette syndrome also remain on track. The company’s digital R&D Day, on March 26, will detail four key metrics it will use to evaluate the efficacy of Sepranolone, the first dedicated treatment for PMDD, which affects 1-in-20 women of reproductive age worldwide.Asarina Pharma’s Phase IIb study into PMDD (premenstrual dysphoric disorder) was conducted in the UK, Germany, Poland and Sweden. Enrolment was completed late in